Activation of factor VIII and mechanisms of cofactor action

Blood Reviews

Volumn 18, Issue 1, 2004, Pages 1-15

  Fay, Philip J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Catalytic rate constant; Factor IXa; Factor VIII; Factor VIIIa; Factor X; Factor Xa; Intrinsic factor Xase; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 COFACTOR; THROMBIN; UNCLASSIFIED DRUG;

BLOOD CLOTTING; CATALYSIS; CATALYST; CONFORMATIONAL TRANSITION; COVALENT BOND; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REACTION TIME; REVIEW;

EID: 1042276751     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(03)00025-0     Document Type: Article

References (117)

1. Do H, Healey JF, Waller EK, Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999;274:19587-92.
2. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984;312:342-7.
3. Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EDG, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984;312:330-7.
4. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984;312:337-42.
5. McMullen BA, Fujikawa K, Davie EW, Hedner U, Ezban M. Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A). Protein Sci 1995;4:740-6.
6. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem 1977;252:5538-46.
7. Fay PJ, Chavin SI, Malone JE, Schroeder D, Young FE, Marder VJ. The effect of carbohydrate depletion on procoagulant activity and in vivo survival of highly purified human factor VIII. Biochim Biophys Acta 1984;800:152-8.
8. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994;269:20095-102.
9. Pan Y, DeFay T, Gitschier J, Cohen FE. Proposed structure of the A domains of factor VIII by homology modelling [letter]. Nat Struct Biol 1995;2:740-4.
10. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997;89:2413-21.
11. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature 1999;402:439-42.
12. Stoylova SS, Lenting PJ, Kemball-Cook G, Holzenburg A. Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers. J Biol Chem 1999;274:36573-8.
13. Fass DN, Knutson GJ, Katzmann JA. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood 1982;59:594-600.
14. Andersson LO, Forsman N, Huang K, Larsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Natl Acad Sci USA 1986;83:2979-83.
15. Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986;871:268-78.
16. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensible for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986;83:5939.
17. Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem 1992;267:13246-50.
18. Bihoreau N, Pin S, Kersabiec AMD, Vodot F, Fontaine-Aupart MP. Copper-atom identification in the active and inactive forms of plasma-derived FVIII and recombinant FVIII-ΔII. Eur J Biochem 1994;220:41-8.
19. Tagliavacca L, Moon N, Dunham WR, Kaufman RJ. Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII. J Biol Chem 1997;272:27428-34.
20. Sudhakar K, Fay PJ. Effects of copper on the structure and function of factor VIII subunits: evidence for an auxiliary role for copper ions in cofactor activity. Biochemistry 1998;37:6874-82.
21. Wakabayashi H, Koszelak ME, Mastri M, Fay PJ. Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. Biochemistry 2001;40:10293-300.
22. Fay PJ. Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys 1988;262:525-31.
23. Wakabayashi H, Schmidt KM, Fay PJ. Ca(2+) binding to both the heavy and light chains of factor VIII is required for cofactor activity. Biochemistry 2002;41:8485-92.
24. 2+ binding to factor VIII subunits and its effect on cofactor activity. Biochemistry 2003;42:145-53.
25. 2+-dependent complex of fragments bound to phospholipid. J Biol Chem 2001;276:19929-36.
26. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424.
27. r-80,000 light chain. Eur J Biochem 1987;166:37-43.
28. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988;263:10451-5.
29. Leyte A, Verbeet MP, Brodniewicz-Proba T, Van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem J 1989;257:679-83.
30. Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipid vesicles. J Biol Chem 1990;265:815-22.
31. Nesheim M, Pittman DD, Giles AR, Fass DN, Wang JH, Slonosky D, Kaufman RJ. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 1991;266:17815-20.
32. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002;99:1215-23.
33. Saenko EL, Shima M, Sarafanov AG. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex. Trends Cardiovasc Med 1999;9:185-92.
34. Nogami K, Shima M, Nishiya K, Hosokawa K, Saenko EL, Sakurai Y, Shibata M, Suzuki H, Tanaka I, Yoshioka A. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation. Blood 2002;99:3993-8.
35. Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci USA 1988;85:2429-33.
36. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 1997;272:18007-14.
37. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986;25:505-12.
38. Barrow RT, Healey JF, Lollar P. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex. J Biol Chem 1994;269:593-8.
39. Ye J, Rezaie AR, Esmon CT. Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101. J Biol Chem 1994;269:17965-70.
40. Esmon CT, Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem 1996;271:13882-7.
41. Myles T, Yun TH, Hall SW, Leung LL. An extensive interaction interface between thrombin and factor V is required for factor V activation. J Biol Chem 2001;276:25143-9.
42. Naski MC, Fenton II JW, Maraganore JM, Olson ST, Shafer JA. The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen. J Biol Chem 1990;265:13484-9.
43. Nogami K, Shima M, Hosokawa K, Nagata M, Koide T, Saenko EL, Tanaka I, Shibata M, Yoshioka A. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000;275:25774-80.
44. Mumford AD, Laffan M, O'Donnell J, McVey JH, Johnson DJ, Manning RA, Kemball-Cook G. A Tyr346→Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 2002;118:589-94.
45. Lollar P, Knutson GJ, Fass DN. Activation of porcine factor VIII:C by thrombin and factor Xa. Biochemistry 1985;24:8056-64.
46. Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem 1990;265:17854-8.
47. Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem 1996;271:6027-32.
48. Parker ET, Pohl J, Blackburn MN, Lollar P. Subunit structure and function of porcine factor Xa-activated factor VIII. Biochemistry 1997;36:9365-73.
49. Nogami K, Wakabayashi H, Fay PJ. Mechanisms of factor VIIIa A1 subunit cleavage by factor Xa during cofactor Inactivation. J Biol Chem 2003;278:1634-41.
50. Rezaie AR. Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J Biol Chem 2000;275:3320-7.
51. Nogami K, Shima M, Hosokawa K, Suzuki T, Koide T, Saenko EL, Scandella D, Shibata M, Kamisue S, Tanaka I, Yoshioka A. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999;274:31000-7.
52. Lapan KA, Fay PJ. Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb Haemost 1998;80:418-22.
53. Saenko EL, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 1995;270:13826-33.
54. Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989;74:1021-4.
55. Hill-Eubanks DC, Parker CG, Lollar P. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci USA 1989;86:6508-12.
56. Saenko EL, Scandella D, Yakhyaev AV, Greco NJ. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem 1998;273:27918-26.
57. Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem 1995;270:8546-52.
58. Donath MS, Lenting PJ, van Mourik JA, Mertens K. The role of cleavage of the light chain at positions Arg1689 or Arg1721 in subunit interaction and activation of human blood coagulation factor VIII. J Biol Chem 1995;270:3648-55.
59. Fay PJ, Mastri M, Koszelak ME, Wakabayashi H. Cleavage of factor VIII heavy chain is required for the functional interaction of a2 subunit with factor IXA. J Biol Chem 2001;276:12434-9.
60. Lollar P, Parker CG. Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 1989;28:666-74.
61. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991;266:8957-62.
62. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990;265:1688-92.
63. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/ porcine factor VIII molecules. J Biol Chem 1992;267:23652-7.
64. Fay PJ, Haidaris PJ, Huggins CF. Role of the COOH-terminal acidic region of A1 subunit in A2 subunit retention in human factor VIIIa. J Biol Chem 1993;268:17861-6.
65. Koszelak Rosenblum ME, Schmidt K, Freas J, Mastri M, Fay PJ. Cofactor activities of factor VIIIa and A2 subunit following cleavage of A1 subunit at Arg336. J Biol Chem 2002;277:11664-9.
66. Koszelak ME, Huggins CF, Fay PJ. Sites in A2 subunit involved in the interfactor VIIIa interaction. J Biol Chem 2000;275:27137-44.
67. O'Brien LM, Huggins CF, Fay PJ. Interacting regions in the A1 and A2 subunits of factor VIIIa identified by zero-length cross-linking. Blood 1997;90:3943-50.
68. Sudhakar K, Fay PJ. Exposed hydrophobic sites in factor VIII and isolated subunits. J Biol Chem 1996;271:23015-21.
69. Curtis JE, Helgerson SL, Parker ET, Lollar P. Isolation and characterization of thrombin-activated human factor VIII. J Biol Chem 1994;269:6246-51.
70. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998;92:3983-96.
71. 2+ and phospholipids to the activation of human blood-coagulation factor X by activated factor IX. Biochem J 1984;223:607-15.
72. Ahmad SS, Scandura JM, Walsh PN. Structural and functional characterization of platelet receptor-mediated factor VIII binding. J Biol Chem 2000;275:13071-81.
73. Lenting PJ, Donath MJ, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 1994;269:7150-5.
74. Duffy EJ, Parker ET, Mutucumarana VP, Johnson AE, Lollar P. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem 1992;267:17006-11.
75. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996;271:1935-40.
76. Lollar P, Parker ET, Curtis JE, Helgerson SL, Hoyer LW, Scott ME, Scandella D. Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest 1994;93:2497-504.
77. Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999;274:29826-30.
78. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994;269:20522-7.
79. Jenkins PV, Freas J, Schmidt KM, Zhou Q, Fay PJ. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood 2002;100:501-8.
80. Mertens K, van Wijngaarden A, Bertina RM, Veltkamp JJ. The functional defect of factor VIII Leiden, a genetic variant of coagulation factor VIII. Thromb Haemost 1985;54:650-3.
81. Jorquera JI, McClntock RA, Roberts JR, McDonald RA, Houghten RA, Fulcher CA. Synthetic peptides derived from residues 698-710 of factor VIII inhibit factor IXa activity. Circulation 1992;86:685 (abstract).
82. Liles DK, Monroe DM, Roberts HR. The factor VIII peptide consisting of amino acids 698-712 enhances factor IXa cleavage of factor X. Blood 1997;90:463a.
83. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998;273:19049-54.
84. Mutucumarana VP, Duffy EJ, Lollar P, Johnson AE. The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study. J Biol Chem 1992;267:17012-21.
85. O'Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem 1995;270:27087-92.
86. Mathur A, Bajaj SP. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. J Biol Chem 1999;274:18477-86.
87. Bajaj SP, Schmidt AE, Mathur A, Padmanabhan K, Zhong D, Mastri M, Fay PJ. Factor IXa: factor VIIIa interaction, helix 330-338 of factor IXa interacts with residues 558-565 and spatially adjacent regions of the A2 subunit of factor VIIIa. J Biol Chem 2001;276:16302-9.
88. Lenting PJ, ter Maat H, Clijsters PP, Donath MJ, van Mourik JA, Mertens K. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. J Biol Chem 1995;270:14884-90.
89. 2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. J Biol Chem 1996;271:25332-7.
90. Christophe OD, Lenting PJ, Kolkman JA, Brownlee GG, Mertens K. Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain. J Biol Chem 1998;273:222-7.
91. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981;256:3433-42.
92. Rawala-Sheikh R, Ahmad SS, Ashby B, Walsh PN. Kinetics of coagulation factor X activation by platelet-bound factor IXa. Biochemistry 1990;29:2606-11.
93. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA 1995;92:9796-800.
94. Hopfner KP, Lang A, Karcher A, Sichler K, Kopetzki E, Brandstetter H, Huber R, Bode W, Engh RA. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure Fold Des 1999;7:989-96.
95. Kolkman JA, Mertens K. Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII. Biochemistry 2000;39:7398-405.
96. 2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X. J Biol Chem 1997;272:23418-26.
97. Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor [comment]. Nature 1996;380:41-6.
98. Sichler K, Kopetzki E, Huber R, Bode W, Hopfner KP, Brandstetter H. Physiological factor IXa activation involves a cooperative conformational rearrangement of the 99-loop. J Biol Chem 2003;278:4121-6.
99. Fay PJ, Koshibu K, Mastri M. The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity. J Biol Chem 1999;274:15401-6.
100. 2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X. J Biol Chem 1997;272:23418-26.
101. Gilbert GE, Arena AA. Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem 1996;271:11120-5.
102. Fay PJ, Mastri M, Koszelak ME. Factor VIIIa cofactor activity shows enhanced ionic strength sensitivity in the absence of phospholipid. Biochim Biophys Acta 2001;1548:159-68.
103. Lapan KA, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997;272:2082-8.
104. Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991;266:12481-6.
105. Lollar P, Knutson GJ, Fass DN. Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid. Blood 1984;63:1303-8.
106. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002;277:18322-33.
107. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996;94:400-6.
108. Celie PH, Van Stempvoort G, Jorieux S, Mazurier C, Van Mourik JA, Mertens K. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function. Br J Haematol 1999;106:792-800.
109. Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999;93:176-83.
110. Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001;97:685-91.
111. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991;266:20139-45.
112. Regan LM, O'Brien LM, Beattie TL, Sudhakar K, Walker FJ, Fay PJ. Activated protein C-catalyzed proteolysis of factor VIIIa alters its interactions within factor Xase. J Biol Chem 1996;271:3982-7.
113. Regan LM, Lamphear BJ, Huggins CF, Walker FJ, Fay PJ. Factor IXa protects factor VIIIa from activated protein C. Factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562. J Biol Chem 1994;269:9445-52.
114. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996;87:4708-17.
115. van 't Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 1997;272:7983-94.
116. O'Brien DP, Johnson D, Byfield P, Tuddenham EG. Inactivation of factor VIII by factor IXa. Biochemistry 1992;31:2805-12.
117. Lamphear BJ, Fay PJ. Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa. Blood 1992;80:3120-6.